Nature Medicine：CAR-T细胞成功治疗自身免疫疾病儿童患者

Core Viewpoint - The article discusses the promising results of CAR-T cell therapy for treating severe autoimmune diseases in children, highlighting a recent study that shows significant clinical improvement in patients with treatment-refractory conditions [3][4]. Group 1: CAR-T Cell Therapy Overview - Since 2017, the FDA has approved multiple CAR-T cell therapies for blood cancers, demonstrating strong therapeutic effects [3]. - Recent clinical research indicates that CAR-T cell therapy shows good treatment outcomes for B cell-mediated autoimmune diseases such as systemic lupus erythematosus and myasthenia gravis [3]. Group 2: Study Details - The study published in Nature Medicine involved 8 pediatric patients with severe/refractory autoimmune diseases, including 4 with systemic lupus erythematosus, 3 with dermatomyositis, and 1 with systemic sclerosis [4][6]. - Patients received a single infusion of 1×10^6/kg of autologous CD19 CAR-T cells, prepared under the hospital exemption pathway [6]. Group 3: Treatment Outcomes - All patients showed significant clinical improvement or remission of autoimmune diseases, evidenced by reduced disease activity scores and signs of organ damage reversal [6][7]. - The median follow-up time was 16.5 months, with all patients experiencing improvements that allowed for the discontinuation of immunomodulators even after B cell reconstitution [7]. Group 4: Safety and Future Research - Adverse events were reported, including mild cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, but all were manageable and no severe infections occurred [7]. - The research team emphasizes the urgent need for formal clinical trials in children and adolescents to confirm these preliminary results and assess the long-term safety of CAR-T cell therapy for autoimmune diseases [7].